Cardiovascular disease (CVD), particularly coronary heart disease (CHD), remains the No. 1 disease killer and continues to rise in the US and the world despite record numbers of statins being prescribed year after year.
METAMORA, Mich., /PRNewswire/ -- Cardiovascular disease (CVD), particularly coronary heart disease (CHD), remains the No. 1 disease killer and continues to rise in the US and the world despite record numbers of statins being prescribed year after year. By 2030, 23.6 million people are predicted to die from CVD (World Heart Federation report). Atherosclerotic plaques lead to coronary heart disease, myocardial infarction, stroke and peripheral arterial disease. Formation of these plaques include the accumulated injury to the lining of the arteries, known as the endothelial glycocalyx. In research and clinical practice, tremendous emphasis has been placed on controlling cholesterol, with limited attention directed toward the repair and maintenance of the endothelial and related factors. Current drugs target CVD symptoms. For example, the symptom of hypertension is treated with diuretics, ACE inhibitors, ARBs, Ca antagonists, β-blockers; Lipedema is treated with statins, bile-sequestrants, fibrates, niacin; and, blood pooling is treated with anti-platelets, anti-coagulants and fibrinolytics. These drugs are at best palliative. Further, the “war on cholesterol” to treat CVD has permeated everyday life, including: policy makers, insurers, health care providers, clinicians, diagnostics and even Wall Street. Moreover, AHA/NIH research is heavily focused on cholesterol and may actually discourage alternative targets and discoveries (2018. Gen Eng Biotech News: 38:8). Collaborating with scientists worldwide, Dr. Joe Tunac, PhD, Medical Scientist, President & Chairman of Arterez LLC, began development of a new paradigm of ‘anti-embolic’ bio-markers and therapeutics in 2011 based on his findings that cholesterol is not the cause of Artherosclerosis, is critical to health and well-being and is therefore a misguided hypothesis for CVD and CHD treatment. Dr. Tunac theorized instead that the disease is due to dysfunctional blood flow, disruption of the vessel’s protective coat (glycocalyx), inflammation and oxidation leading to atheroma (plaque). The result is Arterez’ patented suite of active, synthetic, ‘anti-embolic’ compounds and correlated (to plaque) bio-marker panels targeting the multi-factorial root causes of CVD, including: Embotricin™ (triple-compound, oral synthetic drug) GlycoCardia™ (pre-episodic diagnostic panel/s) The Arterez platform of emerging product innovations may represent a profound breakthrough in the pursuit to reach beyond treatment of symptoms to predictive, preventive and curative outcomes for CVD/CHD and beyond. Arterez, LLC is a Michigan-based biosciences company focused on the development of first-in-class diagnostic panels as well as a triple compound oral therapy targeting the multi-factorial root causes of cardiovascular disease including the repair and maintenance of the Endothelial Glycocalyx, while minimizing the damaging effects of oxidation and reducing inflammation. For more information, contact Mike Brennan, 209775@email4pr.com, 248-931-9091 or visit https://www.arterez.com/ View original content to download multimedia:http://www.prnewswire.com/news-releases/arterez-introduces-a-novel-triple-compound-oral-therapy-and-diagnostic-panels-targeting-the-multi-factorial-root-causes-of-cardiovascular-disease---not-cholesterol---in-human-studies-300799471.html SOURCE Arterez |